subscribeSubscribe
Janssen Submits Phase 3 Study Data to the EMA and FDA for SIRTURO

Janssen Submits Phase 3 Study Data to the EMA and FDA for SIRTURO
PRESS RELEASE
07 Nov 2023
Share Share
After pubic pressure, J&J says it won`t enforce Sirturo patents

After pubic pressure, J&J says it won`t enforce Sirturo patents
Zoey Becker FIERCE PHARMA
02 Oct 2023
Share Share
J&J, Lupin reduce price of TB drug bedaquiline in poor countries

J&J, Lupin reduce price of TB drug bedaquiline in poor countries
Kevin Dunleavy FIERCE PHARMA
01 Sep 2023
Share Share
J&J loses attempt to extend patent in India for tuberculosis drug

J&J loses attempt to extend patent in India for tuberculosis drug
ENDPTS
23 Mar 2023
Share Share
Johnson & Johnson tuberculosis drug`s final patent hearing set for today

Johnson & Johnson tuberculosis drug`s final patent hearing set for today
ECONOMIC TIMES
17 Jan 2023
Share Share
Diabetes, patented TB, HIV drugs enter essential list

Diabetes, patented TB, HIV drugs enter essential list
Teena Thacker ECONOMICTIMES
13 Sep 2022
Share Share
Ayahuasca inspires another biotech startup ATAI; Mylan TB drug gets green light

Ayahuasca inspires another biotech startup ATAI; Mylan TB drug gets green light
John Carroll ENDPTS
22 Jul 2020
Share Share
Johnson & Johnson cuts price of TB drug bedaquiline in poorer countries

Johnson & Johnson cuts price of TB drug bedaquiline in poorer countries
M. Maddipatla REUTERS
07 Jul 2020
Share Share
U.S. FDA Approves New Pediatric Formulation of SIRTURO® (bedaquiline)

U.S. FDA Approves New Pediatric Formulation of SIRTURO® (bedaquiline)
PRESS RELEASE
27 May 2020
Share Share
New TB drug regimen controls resistant disease in 9 of 10 cases: study

New TB drug regimen controls resistant disease in 9 of 10 cases: study
Gene Emery REUTETRS
06 Mar 2020
Share Share